TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29672184
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement (3g HMB, 14g arginine, 14g glutamine)
Study: 26521887
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels > 3 mg/L
Study: 30717614
Drug: Alcohol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.4 g/kg)
Study: 6886965
Drug: Alcohol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (low dose)
Study: 6886965
Drug: Alcohol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (high dose)
Study: 10638391
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral dose of YM087
Study: 10638391
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg i.v. dose of YM087
Study: 7718321
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous magnesium supplements
Study: 1688914
Drug: Mild hypervolaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypervolaemic haemodilution with hydroxyethyl starch (HES) combined with exercise (3 times weekly) for 6 weeks
Study: 1688914
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate combined with exercise (3 times weekly) for 6 weeks
Study: 1688914
Drug: Exercise alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise alone (3 times weekly)
Study: 6586147
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg once weekly)
Study: 6586147
Drug: Penicillamine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillamine (250 mg daily)
Study: 15947609
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg daily for 28 days
Study: 8902991
Drug: Enoxaparin 20
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 20 mg once daily for 10 days
Study: 8902991
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 IU twice daily for 10 days
Study: 1831798
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DMPA plus 100 mg TE monthly (Group I)
Study: 1831798
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DMPA plus 250 mg TE monthly (Group II)
Study: 1831798
Drug: Both steroid
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both steroid regimens (Group I and Group II)
Study: 6753611
Drug: Physostigmine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.125 mg, 0.25 mg, or 0.50 mg)
Study: 6753611
Drug: Physostigmine (previously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (previously associated dose)
Study: 26400993
Drug: Monovalent RV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent RV vaccine (RV1) administered to infants
Study: 25396674
Drug: Topical retapamulin
Normalized name: retapamulin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retapamulin ointment 1% (plus oral placebo), twice daily for 5 days
Study: 25396674
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid (plus placebo ointment) 2 or 3 times daily for 10 days
Study: 20661659
Drug: BIB (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIB (6 months) followed by diet therapy (7 months)
Study: 9641475
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) 7.2 g per day
Study: 7865703
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g of piracetam
Study: 7865703
Drug: 4.8 g
Normalized name: ALCOHOL 74.8 g in 100 g TOPICAL SWAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g of piracetam
Study: 2770269
Drug: L-arginine and
Normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine and L-ornithine (2 grams and 1 gram respectively)
Study: 2770269
Drug: Placebo (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600 mg of calcium and 1 gram of Vitamin C)
Study: 143795
Drug: Live mumps
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live mumps vaccine from the L-3 strain, 1 dose containing 104HAdU50 of mumps virus
Study: 28327932
Drug: Rolapitant 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant 180 mg oral
Study: 26123682
Drug: Higher volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher volume red wine (218 g alcohol/wk)
Study: 26123682
Drug: Lower volume
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower volume red wine (73 g alcohol/wk)
Study: 22001171
Drug: Brand 1
Normalized name: Select Brand 12-Hour 0.05% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 1 (Caballero Smooth Flavor; 0.89 mg ammonium per gram tobacco)
Study: 22001171
Drug: Brand 2
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand 2 (Gauloise Brunes; 3.43 mg ammonium per gram tobacco)
Study: 19500510
Drug: CRRT without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRRT without heparin
Study: 19500510
Drug: CRRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRRT with heparin
Study: 16009365
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl 3.0 g/d
Study: 16009365
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl 3.75 g/d
Study: 11707825
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lorazepam and 2 mg hydromorphone p.o. for the contralateral BMBA
Study: 1591067
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (optimal dose 600 mg/m2)
Study: 1591067
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (600 mg/m2)
Study: 1591067
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (800 mg/m2)
Study: 28066102
Drug: Tinidazole 500
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 500 mg once daily + placebo for 5 days
Study: 28066102
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg twice daily for 5 days
Study: 23027821
Drug: α(1) adrenergic
Normalized name: aminophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: α(1) adrenergic agonist (phenylephrine, PE)
Study: 23027821
Drug: α(2) adrenergic
Normalized name: aminophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: α(2) adrenergic agonist (clonidine, CL)
Study: 9190848
Drug: dynorphin A(1-13)
Normalized name: Dynorphin a
DrugBank: Dynorphin (DB16146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dynorphin A(1-13) 0.1 mg/kg, 0.32 mg/kg, 1 mg/kg (15-min i.v. infusion)
Study: 9190848
Drug: dynorphin A(1-13)
Normalized name: Dynorphin a
DrugBank: Dynorphin (DB16146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dynorphin A(1-13) 1 mg/kg (15-min i.v.) after morphine pretreatment
Study: 9190848
Drug: morphine pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine pretreatment 45 mg/70 kg i.m.
Study: 8398289
Drug: doxifluridine (dFUR)
Normalized name: Trifluridine
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: doxifluridine (dFUR) 4000 mg/m2 daily for 5 days every 28 days
Study: 8398289
Drug: fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil (FU) 500 mg/m2 daily for 5 days every 28 days
Study: 3299905
Drug: Ivermectin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (12 mg single oral dose)
Study: 3299905
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) (50 mg daily for two days and 100 mg twice daily for the following six days, total 1.3 g in eight days)
Study: 18279685
Drug: 7-day hormone-free
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day hormone-free interval (HFI) with placebo
Study: 18279685
Drug: 84/7-day cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84/7-day cycle of 150 mcg LNG/30 mcg EE for 84 days followed by 7 days of 10 mcg EE
Study: 18279685
Drug: 21/7-day cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/7-day cycle of 150 mcg LNG/30 mcg EE for 21 days followed by 7 days of placebo
Study: 10367614
Drug: Counterdependency Scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counterdependency Scale (CDS) administered to patients with chronic pain
Study: 8897388
Drug: CHO‐7 (7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐7 (7% carbohydrate‐electrolyte solution)
Study: 8897388
Drug: CHO‐0/21 (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐0/21 (placebo for first 90 min then a 21% glucose solution)
Study: 1825972
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg etodolac twice daily (n = 31)
Study: 1825972
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin 3-times daily (n = 33)
Study: 19886982
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of isoniazid
Study: 19886982
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a week dosing of isoniazid
Study: 19886982
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing schedules (daily and three times a week)
Study: 9221683
Drug: Aspirin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (125 mg daily)
Study: 9221683
Drug: Pentoxifylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (300 mg daily)
Study: 8424516
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose at 10 g/h during the operation
Study: 23331240
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste (TAP)
Study: 20533106
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Study: 20533106
Drug: 14-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Study: 12684649
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg or 100 microg/kg, single SC injection on day 2 of chemotherapy cycle)
Study: 12684649
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 microg/kg/day, daily SC injections until ANC > or =10 x 10(9)/l or for up to 14 days)
Study: 8574437
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, two inhalations) administered 30 minutes before exercise
Study: 30616380
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus PUFAs (3600 mg/day for three courses, each course included 3 weeks)
Study: 28219692
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg oral once daily for 45 days
Study: 28219692
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg subcutaneous once daily for 45 days
Study: 22136960
Drug: n3-LCPUFA (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: n3-LCPUFA (900 mg daily)
Study: 21318452
Drug: Low-dose omega
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose omega 3 fatty acids (1 gram of fish oil capsule containing 300 mg of eicosapentaenoic acid and docosahexaenoic acid daily for 6 months
Study: 11292954
Drug: MPFF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF (2 tablets daily for 24 weeks)
Study: 11292954
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard compressive therapy plus external treatment)
Study: 2575375
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BRCR and EXP
Study: 2575375
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (BRCR, EXP, Combination)
Study: 12879276
Drug: Single 5-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5-ml intramuscular injection of 250 mg fulvestrant
Study: 12879276
Drug: Two 2.5-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 2.5-ml intramuscular injections with a total of 250 mg fulvestrant
Study: 1610026
Drug: Slo-bid 800
Normalized name: Slo-bid
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slo-bid 800 mg once-a-day in the morning for 2 weeks
Study: 1610026
Drug: Slo-bid 800
Normalized name: Slo-bid
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slo-bid 800 mg once-a-day in the evening for 2 weeks
Study: 27870481
Drug: PF-04937319 (split-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04937319 (split-dose, 150+100 mg)
Study: 27870481
Drug: PF-04937319 (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04937319 (once daily, 300 mg)
Study: 20878044
Drug: Twice/week training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice/week training (group 1)
Study: 8646870
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream, 0.05%
Study: 8646871
Drug: Hydrocortisone-17-butyrate cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone-17-butyrate cream, 0.1%
Study: 7948154
Drug: 0.5% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podophyllotoxin solution
Study: 22685164
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) - 18-24 g protein and 500 kcal per day
Study: 18254433
Drug: Mentoring group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentoring group (tutoring conversational skills to ESL students for 1 hour twice per week for 12 weeks)
Study: 9663841
Drug: Dual or
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual or triple combination therapies including one proton pump inhibitor (30 mg/day lansoprazole or 20 mg/day omeprazole) and one or two antibiotics (500 mg AMOX, 200 mg CLAR or 250 mg MNZ twice a day)
Study: 28506664
Drug: Heliox (70:30)
Normalized name: Helixate
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heliox (70:30) via high flow nasal cannula at 8 L/min for 24 hours
Study: 28506664
Drug: Air–oxygen mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air–oxygen mixture 30% via high flow nasal cannula at 8 L/min for 24 hours
Study: 18576906
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day in HIV-infected patients
Study: 18576906
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day in HIV-negative patients (control)
Study: 1709566
Drug: Inert placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert placebo tablet
Study: 1709566
Drug: No hypnotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hypnotic
Study: 6130752
Drug: Imipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (up to 200 mg/day for 28 weeks)
Study: 31520730
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) - 40,000 IU pancreatin, 3 times daily during meals for 3 months, n = 151
Study: 31236672
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Topical calcipotriol + NB‐UVB)
Study: 28642024
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (n = 38)
Study: 28642024
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (n = 37)
Study: 16786822
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for anxiety
Study: 21477035
Drug: Whitening priming
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening priming agent (Power Swabs) applied prior to whitening treatment.
Study: 21477035
Drug: No whitening
Approvals — FDA: no, EMA: no, PMDA: no
Description: No whitening priming agent applied (control group).
Study: 14692438
Drug: Granisetron treatment
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron treatment
Study: 10758440
Drug: Dolasetron (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (12.5, 25, 50, or 100 mg)
Study: 10758440
Drug: Dolasetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (all doses combined)
Study: 9257201
Drug: Dolasetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (all doses)
Study: 1417173
Drug: Intraportal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal glucose infusion
Study: 8936492
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no glucose infusion)
Study: 3972231
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of interferon (36 and 50 X 10(6) U)
Study: 17668530
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and topical metronidazole gel 1%
Study: 17668530
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole gel 1%
Study: 15383192
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day + statin
Study: 26894175
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% hyaluronic acid therapy for 14 days
Study: 26894175
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo application for 14 days
Study: 18973518
Drug: Phytate-containing mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytate-containing mouthwash (20 mL, twice daily for 1 min)
Study: 17577007
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or other treatment
Study: 16342649
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg orally) from the start of DVd-T treatment (group 1)
Study: 16342649
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg orally) after the start of DVd-T treatment (group 2)
Study: 16342649
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (group 3)
Study: 1900094
Drug: Naloxone (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (1.6 mg/h x 4 h preceded by 1.6 mg iv bolus)
Study: 7128220
Drug: Theophylline (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (low dose: 8.7-13.0 micrograms/ml)
Study: 7128220
Drug: Theophylline (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (high dose: 16.0-23.6 micrograms/ml)
Study: 30409023
Drug: 6% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hypertonic saline (HS) inhalation, twice daily for 52 weeks
Study: 30409023
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic saline (IS) inhalation, twice daily for 52 weeks
Study: 28008093
Drug: Intravenous thrombolytics
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytics (alteplase)
Study: 19824382
Drug: Prostamol-UNO 320
Normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostamol-UNO 320 mg/day for 36 months
Study: 17145264
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg orally 2-3 hours before MRCP
Study: 3612496
Drug: Lignocaine HCl
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine HCl 120 mg
Study: 3612496
Drug: MEGX HCl
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEGX HCl 120 mg
Study: 3612496
Drug: Lignocaine HCl
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine HCl 120 mg + MEGX HCl 120 mg
Study: 25767371
Drug: Lobeglitazone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone (0.5 mg) with warfarin (25 mg) on day 5